Exhibitor Spotlight

Adragos Pharma at CPHI Worldwide Milan 2026 – Exclusive Exhibitor Spotlight

2026-09-23 · · 13 min read

Adragos Pharma brings its end-to-end CDMO capabilities for small molecule finished dosage forms to CPHI Worldwide Milan 2026. With GMP facilities across five countries and regulatory compliance spanning FDA, EMA, and PMDA, the Munich-headquartered company is a notable presence for pharma buyers seeking a capable development and manufacturing partner.

{"schema_version":2,"note":"Rendered from spotlight_page"}

Frequently asked questions

What type of CDMO is Adragos Pharma, and what does it specialize in?

Adragos Pharma is a contract development and manufacturing organization focused specifically on small molecule finished dosage forms. Its capabilities span sterile formulations, semi-solid forms, and non-sterile liquid preparations, supported by formulation development, analytical testing, clinical manufacturing, and commercial GMP production services.

Where are Adragos Pharma's manufacturing facilities located?

The company operates GMP manufacturing facilities across five countries: Germany, France, Greece, Japan, and Switzerland. This distributed network supports clients with international supply chain requirements and multi-market regulatory strategies.

Which regulatory authorities does Adragos Pharma comply with?

Adragos Pharma maintains compliance with three major global regulatory authorities: the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA). This allows clients to pursue multi-market submissions, including the United States, European Union, and Japan, within a single CDMO relationship.

Does Adragos Pharma handle cold chain and controlled substances?

Yes. Adragos Pharma lists cold chain management and narcotics handling as specialist capabilities. These extend the company's addressable program types to include temperature-sensitive products and controlled-substance formulations, which are areas where many CDMOs have limited or no capability.

What is Adragos Pharma's booth number at CPHI Milan 2026?

Booth and hall details for Adragos Pharma at CPHI Worldwide Milan 2026 had not been confirmed at the time this spotlight was published. Visitors should check the official CPHI exhibitor directory or contact Adragos Pharma directly before the event to confirm their location.

How can I schedule a meeting with Adragos Pharma at CPHI Milan?

You can use the contact option on this page to reach out to the Adragos Pharma team ahead of the show. Pre-scheduling a meeting is strongly recommended given the volume of attendees at CPHI Milan. Over 62,000 professionals are expected across the three days.

Is Adragos Pharma relevant if my company is focused on biologics or biosimilars?

Based on publicly available information, Adragos Pharma's stated specialization is small molecule finished dosage forms. Companies whose primary focus is biologics, large molecules, or biosimilars should verify directly with the company whether their current capabilities extend to those program types before scheduling a meeting.